GLP-1 Weight Loss Program in Miami

Results vary by medication and by patient. In major obesity trials, semaglutide 2.4 mg produced average weight loss of about 15% at 68 weeks, while tirzepatide produced average losses up to about 21% at 72 weeks. In a longer tirzepatide maintenance trial, participants who continued treatment averaged about 25% total weight loss at 88 weeks. These are study averages, not guarantees.

Tirzepatide has generally produced greater average weight loss than semaglutide in obesity trials at the doses studied, but that does not mean it is the best choice for every patient. Medical history, diabetes status, side effects, previous response, cost, access, and treatment goals all matter. Dr. Lipman selects treatment based on the individual rather than choosing a medication from weight-loss percentages alone.

Yes. Wegovy is now available as an FDA-approved daily oral semaglutide tablet as well as a weekly injection. Foundayo (orforglipron) was also FDA-approved in 2026 as an oral GLP-1 receptor agonist for chronic weight management in qualifying adults. Oral treatment can be useful for patients who prefer not to use injections, although the medications have different dosing instructions and clinical considerations.

Some patients notice reduced hunger and begin losing weight within the first few weeks, but GLP-1 treatment is designed to work over months, not days. Doses are usually increased gradually to improve tolerability. Weight loss commonly continues as treatment is adjusted, then slows as the body approaches a new weight. A slowdown does not automatically mean the medication has stopped working.

You do not need a fad diet, but food choices still matter. Because GLP-1 medications reduce appetite, it becomes especially important to get enough protein, fluids, fiber, vitamins, and minerals from a smaller amount of food. Dr. Lipman’s approach emphasizes adequate protein and practical calorie control to support fat loss while helping preserve lean muscle and healthy nutrient balance.

The most common side effects are gastrointestinal, including nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reflux. They are often most noticeable when treatment begins or the dose increases. More serious problems can occur, so persistent vomiting, severe abdominal pain, dehydration, or other concerning symptoms should be discussed with a physician promptly.

The answer depends on the specific medication. FDA-approved semaglutide and tirzepatide products are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2, and they should not be used during pregnancy for weight loss. Other gastrointestinal, gallbladder, pancreatic, kidney, diabetes, and medication issues may require additional caution or a different treatment plan. A medical evaluation is essential.

Weight regain is common after GLP-1 therapy is stopped, which is why maintenance should be planned before goal weight is reached. The best long-term strategy varies. It may involve continued medication, dose or interval adjustments when medically appropriate, nutrition and activity changes, or another maintenance approach. Dr. Lipman develops the maintenance plan around the patient’s response, health, and risk of regain.